# PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients

> **NCT04665830** · PHASE3 · COMPLETED · sponsor: **Hamid Al-Essa Organ Transplant Center** · enrollment: 200 (actual)

## Conditions studied

- Kideny Transplant Recipients With High Cardiovascular Risk Score

## Interventions

- **DRUG:** Evolocumab

## Key facts

- **NCT ID:** NCT04665830
- **Lead sponsor:** Hamid Al-Essa Organ Transplant Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-01
- **Primary completion:** 2020-05-01
- **Final completion:** 2020-05-01
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2020-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04665830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04665830, "PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04665830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*